REGN vs SVCO · P/E 14, rev $4.29B vs rev $63.1M
Regeneron Pharmaceuticals Inc (REGN) versus Silvaco Group, Inc. Common Stock (SVCO) — a side-by-side from cached financials, not a winner call.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Silvaco Group, Inc. Common Stock (SVCO) is a software - application company listed on US.
Latest reported REGN revenue for 2026-06-30 was $4.29B. Net income was $1.30B. Revenue was up 19.0% from 2026-03-31 to 2026-06-30. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Latest reported SVCO revenue for 2025-12-31 was $63.1M. Net income was -$41.2M. Revenue was up 5.7% from 2024-12-31 to 2025-12-31. SVCO currently screens at market cap $377.9M.
REGN currently screens at market cap $59.10B and trailing P/E 13.9. SVCO currently screens at market cap $377.9M.
Not investment advice. Open the REGN and SVCO stock pages for the full models.
Not investment advice.